Single-use Bioreactors Market Size & Growth Forecast 2027–2036, By Segments (Usage Type, End-use, Product Scope, Type, Molecule Type, Application, Type of Cell), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Single-use Bioreactors Market size was worth USD 6.1 billion in 2026 and is poised to grow at a 16.53% CAGR between 2027 and 2036, reaching USD 28.16 billion by 2036. The industry revenue for 2027 is assessed at USD 6.95 billion.
Get more details on this report
Request Free Sample ReportSingle-use Bioreactors Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 36.29% share in 2026, driven by its strong biopharmaceutical manufacturing base, mature outsourcing ecosystem, and widespread adoption of flexible biologics production systems.
- Asia Pacific is projected to expand at a 19.04% CAGR as biologics manufacturing capacity grows and facilities increasingly adopt disposable systems for faster setup, scalability, and cost-efficient production.
Segment Momentum
- Lab-scale Production held a 37.76% share in 2026 because it supports early-stage research, pilot studies, and rapid process development through flexible systems with reduced cleaning and changeover requirements.
- Pharmaceutical & Biopharmaceutical Companies are the fastest-growing end users as they expand flexible manufacturing capacity to accelerate development timelines and improve adaptability across multiple biologic production programs.
Market Expansion Drivers
- Flexibility and contamination reduction accelerating biopharmaceutical production adoption.
- Lower operational costs and faster turnaround versus stainless steel systems.
- Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity.
Leading Market Participants
- Major companies in the single-use bioreactors market include Sartorius AG (Germany), Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Danaher Corporation (United States), Lonza Group AG (Switzerland), Getinge AB (Sweden), Eppendorf SE (Germany), PBS Biotech, Inc. (United States), Celltainer Biotech B.V. (Netherlands), Cellexus International Ltd. (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.1 billion
- 2027 Estimated Market Size: USD 6.95 billion.
- Projected Market Size: USD 28.16 billion by 2036
- Growth Forecast: 16.53% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Lab-scale Production (Usage Type) | CROs & CMOs (End-use) | Single-use Bioreactor Systems (Product Scope) | Stirred-tank SUBs (Type) | Vaccines (Molecule Type) | Bioproduction (Application) | Mammalian Cells (Type of Cell)
- Emerging Opportunity Segment: Large-scale Production (Usage Type) | Pharmaceutical & Biopharmaceutical Companies (End-use) | Single-use Bioreactor Systems (Product Scope) | Stirred-tank SUBs (Type) | Gene Modified Cells (Molecule Type) | Bioproduction (Application) | Mammalian Cells (Type of Cell)
Market Growth Drivers and Industry Trends
Flexibility and contamination reduction accelerating biopharmaceutical production adoption
Greater production flexibility and reduced contamination concerns are making disposable processing systems attractive for biopharmaceutical manufacturers seeking adaptable production environments. The single-use bioreactors market will expand as these systems support streamlined manufacturing workflows and allow facilities to respond more efficiently to changing production requirements.
Lower operational costs and faster turnaround versus stainless steel systems
Manufacturers are increasingly evaluating production technologies based on operational efficiency and the time required between manufacturing cycles. For the single-use bioreactors market, lower operating requirements and faster turnaround can improve process efficiency by reducing cleaning and preparation demands associated with conventional stainless steel equipment.
Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity
The expanding development pipeline for biologic products is increasing the need for manufacturing capacity that can accommodate changing production requirements. This environment will support the single-use bioreactors market as contract manufacturing and development organizations expand their capabilities and adopt scalable production systems for biologics manufacturing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Flexibility and contamination reduction accelerating biopharmaceutical production adoption | 2.50% | High | North America, Europe, Asia Pacific | High | Near Term |
| Lower operational costs and faster turnaround versus stainless steel systems | 2.10% | High | North America, Europe | High | Near Term |
| Expanding biologics pipeline and scaling of CMO/CDMO manufacturing capacity | 1.90% | High | North America, Asia Pacific, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the single-use bioreactors market in 2026, representing a 36.29% share, due to the region's advanced biopharmaceutical manufacturing capabilities and strong adoption of flexible production technologies. The expansion of biologics, cell-based therapies, vaccines, and other complex bioprocessing applications is increasing demand for manufacturing systems that can support efficient and adaptable production. Single-use bioreactors offer advantages such as reduced cleaning requirements, lower contamination risk, and greater flexibility for multiproduct manufacturing, making them attractive for modern bioprocessing environments. Strong research and development activity, investments in biomanufacturing infrastructure, and increasing emphasis on accelerating development-to-production timelines are further supporting adoption. Regulatory focus on manufacturing quality and process consistency also encourages the integration of advanced bioprocessing technologies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region in the single-use bioreactors market, supported by expanding biopharmaceutical manufacturing capacity, increasing healthcare investment, and the development of domestic life sciences industries. Growing demand for biologics and advanced therapies is encouraging manufacturers to adopt flexible and scalable production systems capable of supporting changing production requirements. Single-use technologies are particularly attractive where facilities seek to streamline manufacturing processes, reduce infrastructure complexity, and improve operational flexibility. Increasing investments in biotechnology research, vaccine production, and biologics development are strengthening the regional bioprocessing ecosystem. In addition, the expansion of healthcare manufacturing capabilities and growing adoption of modern pharmaceutical production technologies are creating favorable conditions for wider use of single-use bioreactors across Asia Pacific.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Advanced Manufacturing IntegrationGermany integrates single-use bioreactors into highly automated biopharmaceutical production environments. Manufacturers in Germany focus on efficient process validation, equipment compatibility, and sustainable production practices while supporting diverse biologics manufacturing requirements.
France 🇫🇷
Flexible Production StrategyFrance incorporates single-use bioreactors to support clinical manufacturing and specialized biologics production with greater operational flexibility. Organizations in France prioritize efficient facility utilization, faster changeovers, and reliable production processes for innovative therapies.
Italy 🇮🇹
Specialized Biomanufacturing SupportItaly applies single-use bioreactors across research organizations and pharmaceutical manufacturers seeking adaptable production capabilities. Companies in Italy emphasize cost-efficient scale-up, process consistency, and technology upgrades that support expanding biologics development activities.
Japan 🇯🇵
Quality-Focused BioprocessingJapan adopts single-use bioreactors to improve manufacturing flexibility while maintaining stringent quality standards for biologics production. Organizations in Japan emphasize reliable process control, regulatory compliance, and consistent product quality across development and manufacturing stages.
South Korea 🇰🇷
Biologics Capacity DevelopmentSouth Korea continues strengthening biopharmaceutical manufacturing through broader adoption of single-use bioreactor technologies. Companies in South Korea invest in modern production facilities capable of supporting contract manufacturing, process efficiency, and rapid product transitions.
United States 🇺🇸
Bioprocess Expansion CenterThe U.S. continues investing in flexible biomanufacturing capacity where single-use bioreactors support rapid process development and commercial production. Companies across the U.S. prioritize scalable manufacturing platforms, automation, and contamination risk reduction for biologics production.
Segment Leadership and Growth Trends
Single-use Bioreactors Market Share (%), by Usage Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportUsage Type Segment Analysis: Lab-scale Production (Largest Segment) vs Large-scale Production (Fastest-Growing Segment)
Lab-scale production accounted for the largest share of the single-use bioreactors market in 2026, representing 37.76% of the market. These systems are widely used in process development, research, optimization, and early-stage bioprocessing because they provide flexible and efficient platforms for evaluating cell culture and manufacturing conditions. Their disposable format reduces cleaning and sterilization requirements while enabling faster process turnaround, making lab-scale systems particularly valuable for organizations developing and refining biopharmaceutical processes.
Large-scale production is expanding at the fastest pace as biomanufacturing increasingly adopts flexible production technologies capable of supporting efficient commercial-scale operations. Single-use systems can reduce the infrastructure and operational requirements associated with traditional stainless-steel equipment while limiting cross-contamination risks and facilitating faster facility changeovers. Growing demand for scalable bioprocessing and more agile manufacturing workflows is strengthening the adoption of single-use bioreactors in larger production environments.
End-use Segment Analysis: CROs & CMOs (Largest Segment) vs Pharmaceutical & Biopharmaceutical Companies (Fastest-Growing Segment)
CROs & CMOs held the largest share of the single-use bioreactors market in 2026, accounting for 40.97% of the market. Contract research and manufacturing organizations increasingly rely on flexible bioprocessing platforms to support multiple client projects while maintaining efficient facility utilization. Single-use bioreactors are well suited to these environments because they facilitate rapid changeovers, reduce cleaning requirements, and provide greater flexibility when handling different development and manufacturing programs.
Pharmaceutical & biopharmaceutical companies represent the fastest-growing end-use segment as manufacturers increasingly seek adaptable production technologies for biologics and advanced therapies. Single-use bioreactors support streamlined process development and manufacturing while helping organizations respond efficiently to changing production requirements. Their operational flexibility, reduced equipment preparation burden, and suitability for multiproduct environments are encouraging broader adoption across in-house biopharmaceutical production.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Usage Type | Lab-scale Production, Pilot-scale Production, Large-scale Production | Lab-scale Production | Large-scale Production |
| End-use | Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes | CROs & CMOs | Pharmaceutical & Biopharmaceutical Companies |
| Product Scope | Single-use Bioreactor Systems, Single-use Media Bags, Single-use Filtration Assemblies, Others | Single-use Bioreactor Systems | Single-use Bioreactor Systems |
| Type | Stirred-tank SUBs, Wave-induced SUBs, Bubble-column SUBs, Others | Stirred-tank SUBs | Stirred-tank SUBs |
| Molecule Type | Monoclonal Antibodies, Vaccines, Gene Modified Cells, Stem Cells, Others | Vaccines | Gene Modified Cells |
| Application | Research and Development (R&D)or Process Development, Bioproduction | Bioproduction | Bioproduction |
| Type of Cell | Mammalian Cells, Bacterial Cells, Yeast Cells, Others | Mammalian Cells | Mammalian Cells |
Competitive Landscape and Market Positioning
Top players in the single-use bioreactors market:
1. Sartorius AG (Germany)
2. Thermo Fisher Scientific Inc. (United States)
3. Merck KGaA (Germany)
4. Danaher Corporation (United States)
5. Lonza Group AG (Switzerland)
6. Getinge AB (Sweden)
7. Eppendorf SE (Germany)
8. PBS Biotech Inc. (United States)
9. Celltainer Biotech B.V. (Netherlands)
10. Cellexus International Ltd. (United Kingdom)
The single-use bioreactors market is growing rapidly due to increasing demand for flexible biomanufacturing solutions. In the single-use bioreactors market, advancements in disposable system design are improving production scalability. Enhanced process control technologies are also supporting biopharmaceutical innovation.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Sartorius AG (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Getinge AB (Sweden) | |||||||
| Eppendorf SE (Germany) | |||||||
| PBS Biotech Inc. (United States) | |||||||
| Celltainer Biotech B.V. (Netherlands) | |||||||
| Cellexus International Ltd. (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| AGC Biologics | Apr-25 | AGC Biologics integrated two 5,000L Thermo Scientific DynaDrive single-use bioreactors into its Yokohama facility. This investment enhances the site's capability for large-scale mammalian-based biologic production, establishing a sophisticated infrastructure in Japan to meet the growing demand for flexible, high-capacity CDMO manufacturing services. |
| WuXi Biologics | Apr-25 | WuXi Biologics successfully completed the first commercial Process Performance Qualification (PPQ) campaign at its MFG20 facility in Hangzhou. The project utilized a second drug substance line equipped with three 5,000L single-use bioreactors, validating the facility's readiness for large-scale commercial biologics manufacturing and operational scalability. |
| Aragen | Dec-24 | Aragen demonstrated accelerated commercial GMP scale-up capabilities by transferring a monoclonal antibody program from California to Bengaluru in nine months. The successful execution utilized single-use bioreactor production workflows, highlighting the company’s improved tech transfer speed and CDMO execution proficiency for high-risk therapeutic manufacturing. |
| Fujifilm Biotechnologies | Nov-24 | Fujifilm Biotechnologies completed a £400 million expansion of its Teesside facility, adding 19,000L of single-use bioreactor capacity alongside a new innovation center. This investment significantly bolsters the company’s global CDMO antibody production capabilities and process development infrastructure to support increasing biopharmaceutical manufacturing volume requirements. |
| Bora Group | Nov-24 | Bora Group acquired MacroGenics’ CDMO operations for up to $127.5 million, securing a Maryland-based drug-substance facility. The acquisition integrates advanced single-use bioprocessing capabilities into Bora’s biologics platform, expanding its total capacity for late-stage development and commercial-scale manufacturing of complex biologic drug products. |
| WuXi Biologics | Oct-24 | WuXi Biologics expanded its manufacturing footprint by installing three 5,000L single-use bioreactors, effectively increasing total site capacity from 8,000L to 23,000L. This capacity upgrade enhances GMP production throughput and cost-efficiency, reinforcing the industry-wide shift toward large-scale single-use technologies for commercial antibody manufacturing operations. |
| Syngene | Oct-24 | Syngene initiated an expansion of its biomanufacturing infrastructure in India, with a new facility projected to triple its current production capacity. The investment enhances the company’s CDMO service offerings, specifically targeting the demand for large-scale, single-use bioreactor-based production processes for pharmaceutical and biopharmaceutical clients. |
| Thermo Fisher Scientific | Oct-24 | Thermo Fisher Scientific partnered with the Telangana government to establish a 10,000 sq. ft. Bioprocess Design Center in India, with operations commencing in 2025. The center will focus on advancing biotherapeutic development workflows, specifically enhancing technical capabilities in single-use bioreactor design and regional bioprocessing innovation. |
| MicroDigital | Oct-24 | MicroDigital launched a new line of single-use bioreactors in the United States, officially entering the commercial bioprocessing equipment supply market. The technology provides manufacturers with flexible, scalable solutions for biologics production, reflecting the increasing availability and adoption of disposable bioprocessing systems in the North American pharmaceutical sector. |
| Biosphere | Oct-24 | Biosphere secured $8.8 million in seed funding to advance its UV-sterilized, single-use bioreactor platform. The investment is targeted at scaling technology designed to lower biomanufacturing costs and improve process efficiency, representing a strategic effort to introduce novel sterilization methods into standard single-use production workflows. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Single-use Bioreactors Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Facility Type | Biopharmaceutical Manufacturing Facilities, Contract Manufacturing Facilities, Contract Research Facilities, Academic & Research Facilities |
| Procurement Model | Direct Procurement, Distributor-Based Procurement, Integrated Platform Procurement |
| Service Model | Equipment & Consumables Supply, Managed Bioprocess Services, Equipment-as-a-Service |
Single-use Bioreactors Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Biopharmaceutical Manufacturing Capacity Expansion Outlook |
|
| CDMO Adoption and Outsourcing Opportunity Assessment |
|
| Single-use Technology Adoption Benchmarking |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of single-use bioreactors?
How is the single-use bioreactors industry projected to perform over the next decade?
How is the shift toward flexible and contamination-controlled manufacturing influencing adoption in the single-use bioreactors market?
Why is expansion of outsourced biomanufacturing capacity accelerating growth in the single-use bioreactors market?
Why is Lab-scale Production the largest usage type in the single-use bioreactors market?
Why are Pharmaceutical & Biopharmaceutical Companies the fastest-growing end-use segment in the single-use bioreactors market?
What factors make North America the leading region in the single-use bioreactors market?
Why is Asia Pacific experiencing the fastest growth in the single-use bioreactors market?
Which organizations are considered leaders in the single-use bioreactors landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization